Table 3

Key studies of TNF-blocker therapy in ankylosing spondylitis

Outcomes reported

Therapy

Published study

Primary outcome

Radiologic outcome

Follow-up

BASDAI

BASFI

BASMI

QoL

EMS

Fatigue

CRP/ ESR

Infliximab

Braun and colleagues [96-100]

50% improvement in BASDAI at week 12

mSASSS

5 years

x

x

x

x

x

x

Infliximab

Marzo-Ortega and colleagues [101]

Change in BASDAI at weeks 4, 10, 30

MRI inflammatory lesions

30 weeks

x

x

x

x

x

Infliximab

van der Heijde and colleagues [83,102]

ASAS 20 at week 24

mSASSS

8 years

x

x

x

x

x

x

x

Etanercept

Davis and colleagues [103-105], van der Heijde and colleagues [84]

ASAS 20 at week 12

mSASSS

16 years

x

x

x

x

x

Etanercept

Calin and colleagues [106], Dijkmans and colleagues [107]

ASAS 20 at week 12

mSASSS

8 years

x

x

x

x

x

Adalimumab

van der Heijde and colleagues [108]

ASAS 20 at week 12

NA

24 weeks

x

x

x

x

x

x

Golimumab

Inman and colleagues [109]

ASAS 20 at week 14

NA

24 weeks

x

x

x

x

x

x

ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate; EMS, early morning stiffness; MRI, magnetic resonance imaging; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NA, not applicable; QoL, quality of life.

Schett et al. Arthritis Research & Therapy 2011 13(Suppl 1):S4   doi:10.1186/1478-6354-13-S1-S4